|
2025-01-02 |
2024-12-30 |
K
Kauf
|
CHANG NANCY T
Nicht geschäftsführender Verwaltungsratsmitglied
Large shareholder
|
7.644.932
+inf%
0,07
499.979 USD
|
7.644.932
+inf%
|
0,07
|
499.979 USD
|
|
|
2024-08-20 |
2024-08-16 |
V
Verkauf
|
Sorensen Mel
President and CEO
Geschäftsführender Verwaltungsratsmitglied
|
67.015
-20.2%
0,07
4.825 USD
|
67.015
-20.2%
|
0,07
|
4.825 USD
|
|
|
2024-02-26 |
2024-02-08 |
K
Kauf
|
Schneid Yair
Large shareholder
|
150.000
+1.9%
0,17
25.650 USD
|
150.000
+1.9%
|
0,17
|
25.650 USD
|
|
|
2024-02-26 |
2024-02-07 |
K
Kauf
|
Schneid Yair
Large shareholder
|
150.000
+1.9%
0,17
25.935 USD
|
150.000
+1.9%
|
0,17
|
25.935 USD
|
|
|
2024-02-26 |
2024-02-07 |
K
Kauf
|
Schneid Yair
Large shareholder
|
25.000
+0.3%
0,17
4.250 USD
|
25.000
+0.3%
|
0,17
|
4.250 USD
|
|
|
2024-02-26 |
2024-02-06 |
K
Kauf
|
Schneid Yair
Large shareholder
|
25.000
+0.3%
0,20
5.025 USD
|
25.000
+0.3%
|
0,20
|
5.025 USD
|
|
|
2024-02-26 |
2024-02-05 |
K
Kauf
|
Schneid Yair
Large shareholder
|
97.402
+1.3%
0,18
17.922 USD
|
97.402
+1.3%
|
0,18
|
17.922 USD
|
|
|
2024-02-26 |
2024-01-30 |
K
Kauf
|
Schneid Yair
Large shareholder
|
335.000
+4.6%
0,18
60.635 USD
|
335.000
+4.6%
|
0,18
|
60.635 USD
|
|
|
2024-02-26 |
2024-01-29 |
K
Kauf
|
Schneid Yair
Large shareholder
|
150.000
+2.1%
0,18
27.000 USD
|
150.000
+2.1%
|
0,18
|
27.000 USD
|
|
|
2023-03-20 |
2023-03-16 |
K
Kauf
|
Bachleda Mark
Chief Commercial Officer
Führungsperson
|
11.000
+inf%
2,25
24.717 USD
|
11.000
+inf%
|
2,25
|
24.717 USD
|
|
|
2023-03-14 |
2023-03-13 |
K
Kauf
|
Degnan Chris
Chief Financial Officer
Führungsperson
|
10.000
+inf%
1,96
19.593 USD
|
10.000
+inf%
|
1,96
|
19.593 USD
|
|
|
2023-03-14 |
2023-03-10 |
K
Kauf
|
Sorensen Mel
President and CEO
Geschäftsführender Verwaltungsratsmitglied
|
100.000
+43.1%
1,68
168.120 USD
|
100.000
+43.1%
|
1,68
|
168.120 USD
|
|
|
2021-12-20 |
2021-12-17 |
K
Kauf
|
West Linda
Nicht geschäftsführender Verwaltungsratsmitglied
|
20.000
+50.0%
2,74
54.804 USD
|
20.000
+50.0%
|
2,74
|
54.804 USD
|
|
|
2021-09-03 |
2021-09-01 |
GV
Geplanter Verkauf
|
HOLMLUND JON T
Chief Medical Officer
Führungsperson
|
47.756
-100.0%
8,47
404.498 USD
|
47.756
-100.0%
|
8,47
|
404.498 USD
|
|
|
2021-06-17 |
2021-06-15 |
K
Kauf
|
West Linda
Nicht geschäftsführender Verwaltungsratsmitglied
|
10.000
+33.3%
9,13
91.300 USD
|
10.000
+33.3%
|
9,13
|
91.300 USD
|
|
|
2021-06-04 |
2021-06-02 |
K
Kauf
|
West Linda
Nicht geschäftsführender Verwaltungsratsmitglied
|
10.000
+50.0%
8,65
86.511 USD
|
10.000
+50.0%
|
8,65
|
86.511 USD
|
|
|
2021-06-03 |
2021-06-01 |
K
Kauf
|
Alleva Lawrence M
Nicht geschäftsführender Verwaltungsratsmitglied
|
4.045
+inf%
8,59
34.741 USD
|
4.045
+inf%
|
8,59
|
34.741 USD
|
|
|
2021-06-02 |
2021-06-01 |
K
Kauf
|
West Linda
Nicht geschäftsführender Verwaltungsratsmitglied
|
10.000
+100.0%
8,64
86.381 USD
|
10.000
+100.0%
|
8,64
|
86.381 USD
|
|
|
2021-06-02 |
2021-05-28 |
K
Kauf
|
West Linda
Nicht geschäftsführender Verwaltungsratsmitglied
|
10.000
+inf%
8,64
86.410 USD
|
10.000
+inf%
|
8,64
|
86.410 USD
|
|
|
2021-02-19 |
2021-02-18 |
V
Verkauf
|
Novo Holdings A/S
Large shareholder
|
500.000
-16.9%
10,58
5.290.000 USD
|
500.000
-16.9%
|
10,58
|
5.290.000 USD
|
|
|
2020-11-17 |
2020-11-13 |
K
Kauf
|
Alleva Lawrence M
Nicht geschäftsführender Verwaltungsratsmitglied
|
2.325
+58.1%
10,22
23.771 USD
|
2.325
+58.1%
|
10,22
|
23.771 USD
|
|
|
2020-11-16 |
2020-11-13 |
V
Verkauf
|
Sussman Joel F.
Chief Accounting Officer
Führungsperson
|
10.000
-100.0%
10,32
103.197 USD
|
10.000
-100.0%
|
10,32
|
103.197 USD
|
|
|
2020-11-16 |
2020-11-12 |
V
Verkauf
|
Sussman Joel F.
Chief Accounting Officer
Führungsperson
|
10.000
-100.0%
10,06
100.627 USD
|
10.000
-100.0%
|
10,06
|
100.627 USD
|
|
|
2020-10-28 |
2020-10-26 |
GV
Geplanter Verkauf
|
HOLMLUND JON T
Chief Medical Officer
Führungsperson
|
2.244
-100.0%
15,00
33.660 USD
|
2.244
-100.0%
|
15,00
|
33.660 USD
|
|
|
2020-10-19 |
2020-10-15 |
V
Verkauf
|
Novo Holdings A/S
Large shareholder
|
450.000
-13.2%
11,00
4.950.000 USD
|
450.000
-13.2%
|
11,00
|
4.950.000 USD
|
|
|
2020-10-07 |
2020-10-06 |
GV
Geplanter Verkauf
|
HOLMLUND JON T
Chief Medical Officer
Führungsperson
|
10.536
-100.0%
12,00
126.432 USD
|
10.536
-100.0%
|
12,00
|
126.432 USD
|
|
|
2020-10-07 |
2020-10-05 |
GV
Geplanter Verkauf
|
HOLMLUND JON T
Chief Medical Officer
Führungsperson
|
100
-100.0%
12,00
1.200 USD
|
100
-100.0%
|
12,00
|
1.200 USD
|
|
|
2020-06-22 |
2020-06-19 |
V
Verkauf
|
Novartis Bioventures Ltd
Former 10% Owner
|
1.001.312
-28.9%
8,25
8.260.824 USD
|
1.001.312
-28.9%
|
8,25
|
8.260.824 USD
|
|
|
2020-06-22 |
2020-06-18 |
V
Verkauf
|
Novartis Bioventures Ltd
Former 10% Owner
|
900
-0.0%
9,04
8.136 USD
|
900
-0.0%
|
9,04
|
8.136 USD
|
|
|
2020-06-17 |
2020-06-17 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
4.622
-0.1%
9,27
42.846 USD
|
4.622
-0.1%
|
9,27
|
42.846 USD
|
|
|
2020-06-17 |
2020-06-16 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
8.600
-0.2%
9,30
79.980 USD
|
8.600
-0.2%
|
9,30
|
79.980 USD
|
|
|
2020-06-17 |
2020-06-15 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
6.164
-0.2%
9,05
55.784 USD
|
6.164
-0.2%
|
9,05
|
55.784 USD
|
|
|
2020-06-12 |
2020-06-12 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
1.500
-0.0%
9,19
13.785 USD
|
1.500
-0.0%
|
9,19
|
13.785 USD
|
|
|
2020-06-12 |
2020-06-11 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
7.200
-0.2%
9,21
66.312 USD
|
7.200
-0.2%
|
9,21
|
66.312 USD
|
|
|
2020-06-12 |
2020-06-10 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
8.532
-0.2%
9,46
80.713 USD
|
8.532
-0.2%
|
9,46
|
80.713 USD
|
|
|
2020-06-09 |
2020-06-09 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
7.000
-0.2%
9,38
65.660 USD
|
7.000
-0.2%
|
9,38
|
65.660 USD
|
|
|
2020-06-09 |
2020-06-08 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
5.659
-0.2%
9,66
54.666 USD
|
5.659
-0.2%
|
9,66
|
54.666 USD
|
|
|
2020-06-09 |
2020-06-05 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
8.652
-0.2%
9,66
83.578 USD
|
8.652
-0.2%
|
9,66
|
83.578 USD
|
|
|
2020-06-04 |
2020-06-04 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
4.088
-0.1%
9,55
39.040 USD
|
4.088
-0.1%
|
9,55
|
39.040 USD
|
|
|
2020-06-04 |
2020-06-03 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
5.208
-0.1%
9,78
50.934 USD
|
5.208
-0.1%
|
9,78
|
50.934 USD
|
|
|
2020-06-04 |
2020-06-02 |
V
Verkauf
|
Novartis Bioventures Ltd
Large shareholder
|
5.669
-0.2%
9,68
54.876 USD
|
5.669
-0.2%
|
9,68
|
54.876 USD
|
|
|
2020-05-28 |
2020-05-26 |
GV
Geplanter Verkauf
|
HOLMLUND JON T
Chief Medical Officer
Führungsperson
|
692
-100.0%
12,00
8.304 USD
|
692
-100.0%
|
12,00
|
8.304 USD
|
|
|
2020-05-22 |
2020-05-21 |
GV
Geplanter Verkauf
|
HOLMLUND JON T
Chief Medical Officer
Führungsperson
|
1.174
-100.0%
12,00
14.088 USD
|
1.174
-100.0%
|
12,00
|
14.088 USD
|
|
|
2020-05-22 |
2020-05-20 |
GV
Geplanter Verkauf
|
HOLMLUND JON T
Chief Medical Officer
Führungsperson
|
969
-100.0%
12,00
11.628 USD
|
969
-100.0%
|
12,00
|
11.628 USD
|
|
|
2020-05-12 |
2020-05-12 |
GV
Geplanter Verkauf
|
HOLMLUND JON T
Chief Medical Officer
Führungsperson
|
671
-100.0%
12,00
8.052 USD
|
671
-100.0%
|
12,00
|
8.052 USD
|
|
|
2020-05-12 |
2020-05-11 |
GV
Geplanter Verkauf
|
HOLMLUND JON T
Chief Medical Officer
Führungsperson
|
185
-100.0%
12,00
2.220 USD
|
185
-100.0%
|
12,00
|
2.220 USD
|
|
|
2020-05-12 |
2020-05-08 |
GV
Geplanter Verkauf
|
HOLMLUND JON T
Chief Medical Officer
Führungsperson
|
5.102
-100.0%
12,00
61.224 USD
|
5.102
-100.0%
|
12,00
|
61.224 USD
|
|
|
2020-05-07 |
2020-05-07 |
GV
Geplanter Verkauf
|
HOLMLUND JON T
Chief Medical Officer
Führungsperson
|
2.059
-100.0%
12,00
24.709 USD
|
2.059
-100.0%
|
12,00
|
24.709 USD
|
|
|
2020-05-07 |
2020-05-06 |
GV
Geplanter Verkauf
|
HOLMLUND JON T
Chief Medical Officer
Führungsperson
|
1.489
-100.0%
12,00
17.868 USD
|
1.489
-100.0%
|
12,00
|
17.868 USD
|
|
|
2020-05-07 |
2020-05-05 |
GV
Geplanter Verkauf
|
HOLMLUND JON T
Chief Medical Officer
Führungsperson
|
3.064
-100.0%
12,16
37.258 USD
|
3.064
-100.0%
|
12,16
|
37.258 USD
|
|
|
2019-12-17 |
2019-12-13 |
K
Kauf
|
Alleva Lawrence M
Nicht geschäftsführender Verwaltungsratsmitglied
|
4.000
+inf%
9,78
39.139 USD
|
4.000
+inf%
|
9,78
|
39.139 USD
|
|
|
2019-11-14 |
2019-11-12 |
K
Kauf
|
Clarus IV-A, L.P.
Large shareholder
|
19.423
+17.5%
12,00
233.076 USD
|
19.423
+17.5%
|
12,00
|
233.076 USD
|
|
|
2019-11-14 |
2019-11-12 |
K
Kauf
|
Clarus IV-A, L.P.
Large shareholder
|
97.131
+17.5%
12,00
1.165.572 USD
|
97.131
+17.5%
|
12,00
|
1.165.572 USD
|
|
|
2019-11-14 |
2019-11-12 |
K
Kauf
|
Clarus IV-A, L.P.
Large shareholder
|
52.660
+17.5%
12,00
631.920 USD
|
52.660
+17.5%
|
12,00
|
631.920 USD
|
|
|
2019-11-14 |
2019-11-12 |
K
Kauf
|
Clarus IV-A, L.P.
Large shareholder
|
80.786
+17.5%
12,00
969.432 USD
|
80.786
+17.5%
|
12,00
|
969.432 USD
|
|
|
2019-11-14 |
2019-11-12 |
K
Kauf
|
Novo Holdings A/S
SEE REMARKS
Large shareholder
|
500.000
+17.2%
12,00
6.000.000 USD
|
500.000
+17.2%
|
12,00
|
6.000.000 USD
|
|
|
2019-11-14 |
2019-11-12 |
K
Kauf
|
Blackstone Clarus GP L.P.
Large shareholder
|
19.423
+17.5%
12,00
233.076 USD
|
19.423
+17.5%
|
12,00
|
233.076 USD
|
|
|
2019-11-14 |
2019-11-12 |
K
Kauf
|
Blackstone Clarus GP L.P.
Large shareholder
|
97.131
+17.5%
12,00
1.165.572 USD
|
97.131
+17.5%
|
12,00
|
1.165.572 USD
|
|
|
2019-11-14 |
2019-11-12 |
K
Kauf
|
Blackstone Clarus GP L.P.
Large shareholder
|
52.660
+17.5%
12,00
631.920 USD
|
52.660
+17.5%
|
12,00
|
631.920 USD
|
|
|
2019-11-14 |
2019-11-12 |
K
Kauf
|
Blackstone Clarus GP L.P.
Large shareholder
|
80.786
+17.5%
12,00
969.432 USD
|
80.786
+17.5%
|
12,00
|
969.432 USD
|
|
|
2019-11-12 |
2019-11-12 |
K
Kauf
|
Sofinnova Venture Partners IX, L.P.
Large shareholder
|
750.000
+32.1%
12,00
9.000.000 USD
|
750.000
+32.1%
|
12,00
|
9.000.000 USD
|
|
|
2019-11-12 |
2019-11-12 |
K
Kauf
|
New Enterprise Associates 14, L.P.
Large shareholder
|
416.666
+10.6%
12,00
4.999.992 USD
|
416.666
+10.6%
|
12,00
|
4.999.992 USD
|
|
|
2019-11-12 |
2019-11-12 |
K
Kauf
|
Novartis Bioventures Ltd
Large shareholder
|
250.000
+7.6%
12,00
3.000.000 USD
|
250.000
+7.6%
|
12,00
|
3.000.000 USD
|
|
